APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sagility-india" target="_blank" data-smartkarma-citation="entities:43717:1" rel="noopener">Sagility India (2058883D IN)</a> (Sagility) raised around US$250m in its India IPO in Nov 2024. The lockup on its pre-IPO investors is set to expire soon.</li>
<li>Sagility is a pure-play healthcare focused solutions and services provider to Payers (U.S. health insurance companies), and Providers (primarily hospitals, physicians, and diagnostic and medical devices companies).</li>
<li>In this note, we will talk about the lockup dynamics, possible placement and updates since our last note.</li>
</ul>



Sagility India (2058883D IN) (Sagility) raised around US$250m in its India IPO in Nov 2024. The lockup on its pre-IPO investors is set to expire soon.
Sagility is a pure-play healthcare focused solutions and services provider to Payers (U.S. health insurance companies), and Providers (primarily hospitals, physicians, and diagnostic and medical devices companies).
In this note, we will talk about the lockup dynamics, possible placement and updates since our last note.


Sagility India IPO Lockup - US$1.5bn Lockup Release; PE Promoter Will Have to Trim for Free-Float

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Veeva Systems Inc Class A / Equity Bottom-Up

<ul><li>Veeva Systems, a prominent player in the life sciences cloud software industry, recently reported its fiscal 2025 fourth-quarter and full-year results.</li><li>The company demonstrated strength across its business segments, finishing the year with total revenue reaching $2.75 billion and non-GAAP operating income of $1.15 billion for the year.</li><li>The fourth quarter alone contributed $721 million in revenue, outperforming their guidance.</li></ul>

Veeva Systems, a prominent player in the life sciences cloud software industry, recently reported its fiscal 2025 fourth-quarter and full-year results.The company demonstrated strength across its business segments, finishing the year with total revenue reaching $2.75 billion and non-GAAP operating income of $1.15 billion for the year.The fourth quarter alone contributed $721 million in revenue, outperforming their guidance.

Automation Meets Flexibility: How Veeva Systems Is Disrupting Pharma Tech With AI & CRM Integration!

<ul><li>Veeva Systems reported a robust performance for its fiscal 2025 third quarter that ended on October 31, 2024.</li><li>The company delivered revenue of $699 million, surpassing guidance, and achieved a non-GAAP operating income of $304 million.</li><li>This indicates strong operational execution and continued innovation, which have been key differentiators for the company.</li></ul>

Veeva Systems reported a robust performance for its fiscal 2025 third quarter that ended on October 31, 2024.The company delivered revenue of $699 million, surpassing guidance, and achieved a non-GAAP operating income of $304 million.This indicates strong operational execution and continued innovation, which have been key differentiators for the company.

Veeva Systems’ Vault CRM Revolution: How Smart Migrations Are Fueling Industry Domination! - Major Drivers

Clarence Chu

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/indegene-limited" target="_blank" data-smartkarma-citation="entities:36629:1" rel="noopener">Indegene Limited (1864095D IN)</a> was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024. </li>
<li>Indegene is a “digital-first” commercialisation firm with an exclusive focus on the global life sciences industry.</li>
<li>In this note, we will talk about the lock-up dynamics and updates since our last note.</li>
</ul>



Indegene Limited (1864095D IN) was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024. 
Indegene is a “digital-first” commercialisation firm with an exclusive focus on the global life sciences industry.
In this note, we will talk about the lock-up dynamics and updates since our last note.


Indegene Lockup Expiry - US$1bn+ Lockup Release, Some Could Look to Book 3x Gain

<ul><li>Veeva Systems reported its fiscal second quarter results for 2025, showcasing strong performance with totals exceeding guidance.</li><li>For the quarter ending July 31, 2024, the company achieved total revenue of $676 million and a non-GAAP operating income of $280 million.</li><li>These figures reflect Veeva System's robust product strategy execution, including strategic customer wins and key product expansions, such as the release of Veeva Site Connect and the introduction of Service Center in the CRM suite.</li></ul>

Veeva Systems reported its fiscal second quarter results for 2025, showcasing strong performance with totals exceeding guidance.For the quarter ending July 31, 2024, the company achieved total revenue of $676 million and a non-GAAP operating income of $280 million.These figures reflect Veeva System's robust product strategy execution, including strategic customer wins and key product expansions, such as the release of Veeva Site Connect and the introduction of Service Center in the CRM suite.

Veeva Systems: Continued Expansion and Adoption of Vault Platform As A Key Growth Lever! - Major Drivers

United States

Veeva Systems Inc. provides cloud-based business services. The Company offers enterprise applications, multichannel platform, customer relationship, and content management solutions. Veeva Systems serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Veeva Systems Inc Class A (VEEV US)

Sagility India IPO Lockup - US$1.5bn Lockup Release; PE Promoter Will Have to Trim for Free-Float

Sagility B.V. plans to offload up to 15.02% stake in Sagility India via block deals worth INR26.7bn (US$314.7m). The secondary share sale is priced...

Akshat Shah

Automation Meets Flexibility: How Veeva Systems Is Disrupting Pharma Tech With AI & CRM Integration!

Veeva Systems, a prominent player in the life sciences cloud software industry, recently reported its fiscal 2025 fourth-quarter and full-year...

Baptista Research

Veeva Systems’ Vault CRM Revolution: How Smart Migrations Are Fueling Industry Domination! - Major Drivers

Veeva Systems reported a robust performance for its fiscal 2025 third quarter that ended on October 31, 2024. The company delivered revenue of...

Baptista Research

Indegene Lockup Expiry - US$1bn+ Lockup Release, Some Could Look to Book 3x Gain

Indegene Limited (1864095D IN) was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024.

Clarence Chu

Veeva Systems: Continued Expansion and Adoption of Vault Platform As A Key Growth Lever! - Major Drivers

Veeva Systems reported its fiscal second quarter results for 2025, showcasing strong performance with totals exceeding guidance. For the quarter...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)